$Icecure Medical(ICCM.US) surged 235% the previous day on the clinical data from the ProSense cryoablation group, only to give back over ten percentage points the next day. The small-sample data showing 90% non-recurrence for kidney tumors is indeed impressive, but clinical rallies for small-cap medical device stocks can be as fast to retreat as they are to rise. This is profit-taking after the data release, not a new negative catalyst. At this level, should one chase this clinical milestone, or wait for it to digest the previous day's emotional bubble? I'd wait, because a stock that doubles in a day rarely sees its emotional tide recede in just one day.